-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-151 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-151 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-151 in Endometrial Cancer Drug Details: AMT-151 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-151 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMT-151 in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMT-151 in Peritoneal Cancer Drug Details: AMT-151 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMT-151 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMT-151 in Solid Tumor Drug Details: AMT-151 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRT-2527 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRT-2527 in Mantle Cell Lymphoma Drug Details: PRT-2527 is under development...
-
Product Insights
NewBiliary Tumor – Drugs In Development, 2024
Empower your strategies with our Biliary Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Bile duct cancer, or cholangiocarcinoma, is a rare malignancy arising from malignant cells forming in the bile ducts. It presents in two main types: intrahepatic, occurring inside the liver, and extrahepatic, forming outside the liver. Extrahepatic bile duct cancer further divides into perihilar, found where the right and left bile ducts meet, and distal, located where liver and gallbladder ducts merge. Symptoms...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Magrolimab in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Magrolimab in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug Details: Magrolimab is under development for the...
-
Product Insights
NewBasal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024
Empower your strategies with our Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024 report and make more profitable business decisions. Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include a waxy bump; a scaly, brown, or flesh-colored patch; or a white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery. The Basal Cell Carcinoma (Basal Cell Epithelioma) drugs in...
-
Product Insights
NewMalignant Pleural Mesothelioma – Drugs In Development, 2024
Empower your strategies with our Malignant Pleural Mesothelioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant pleural mesothelioma is a rare cancer of the lining around the lungs, called the pleura. It is caused by asbestos fibers. After inhalation, the fibers can embed in the pleura, causing inflammation and scarring. Over time, these processes can lead to the development of mesothelioma tumors. The most common symptoms of pleural mesothelioma include difficulty breathing, swelling, back pain, and...
-
Product Insights
NewLung Adenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...